Yip, Steven

Medical Oncology

Clinical Associate Professor

Biography

Dr. Steven Yip is a Staff Medical Oncologist at the Arthur Child Cancer Centre and a Clinical Associate Professor of Medicine at the University of Calgary. He is the Medical Lead of Precision Oncology & Experimental Therapeutics (POET), a precision oncology program that has connected over 1,000 patients with advanced cancer to molecular testing. He is the Southern Alberta GU Tumour Group Chair. He helped establish PSMA PET/CT imaging in Southern Alberta. He has an academic focus on precision oncology, translational research, PSMA PET/CT imaging and novel radiopharmaceutical and theranostics drug development in advanced prostate cancer. He completed his medical oncology clinical and translational research genitourinary fellowship at BC Cancer. He received his MD at the University of Alberta and trained at the University of British Columbia and the University of Calgary. He has a Masters of Science in Health Research Methodology from McMaster University. He was named to Avenue Calgary’s Top 40 Under 40 in 2023.

Research Interests:

  • Translational research in prostate cancer, with biomarker polyomic studies and real-world outcomes research
  • Novel radiopharmaceutical and theranostics drug development in advanced prostate cancer
  • PSMA PET/CT imaging in prostate cancer

Area of Focus

Research Interests:

  • Translational research in prostate cancer, with biomarker polyomic studies and real-world outcomes research
  • Novel radiopharmaceutical and theranostics drug development in advanced prostate cancer
  • PSMA PET/CT imaging in prostate cancer

Summary of Research

  1. Reimers MA, Yip SM (Co-First Authors), Zhang L, Cieslik M, Dhawan M, Montgomery B, Wyatt AW, Chi KN, Small EJ, Chinnaiyan AM, Alva AS, Feng FY, Chou J. Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer. Eur Urol. 2019. 77(3):333-341. doi: 10.1016/j.eururo.2019.09.036
  2. Yip SM, Cheung WY, Aprikian A, Stoelzel M, Wong K., Pranzo A, Chilelli A, et al. (2025). Treatment intensification in metastatic castration-sensitive prostate cancer: a real-world study in Alberta, Canada. Future Oncology. 21(10), 1197–1207. https://doi.org/10.1080/14796694.2025.2479374
  3. Yip SM, Wells C, Moreira R, Wong A, Srinivas S, Beuselinck B, Porta C, Sim HW, Ernst DS, Rini BI, Yuasa T, Basappa NS, Kanesvaran R, Wood LA, Canil C, Kapoor A, Fu SYF, Choueiri TK, Heng DYC. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Cancer. 2018 Sep 15; 124(18):3677-3683. doi:10.1002/cncr.31595
  4. Yip SM, Laird AD, Agarwal N, Zschäbitz S, Fizazi K, Matsubara N, Joung JY, Karsh LI, Carles J, Fay AP, Piulats JM, Fong PCC, Liu G, Albacker LA, Pasquina LW, Chelliserry J, Healy CG Lin X, Kalac M,. Azad AA. Circulating Tumour DNA and Cells as Prognostic and Predictive Biomarkers of Efficacy in, and Molecular Profiling of, Patients with mCRPC in the TALAPRO-2 Study. Lancet Oncology (In Review)

Area Of Focus

Research Interests:

  • Translational research in prostate cancer, with biomarker polyomic studies and real-world outcomes research
  • Novel radiopharmaceutical and theranostics drug development in advanced prostate cancer
  • PSMA PET/CT imaging in prostate cancer

Summary Of Research

  1. Reimers MA, Yip SM (Co-First Authors), Zhang L, Cieslik M, Dhawan M, Montgomery B, Wyatt AW, Chi KN, Small EJ, Chinnaiyan AM, Alva AS, Feng FY, Chou J. Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer. Eur Urol. 2019. 77(3):333-341. doi: 10.1016/j.eururo.2019.09.036
  2. Yip SM, Cheung WY, Aprikian A, Stoelzel M, Wong K., Pranzo A, Chilelli A, et al. (2025). Treatment intensification in metastatic castration-sensitive prostate cancer: a real-world study in Alberta, Canada. Future Oncology. 21(10), 1197–1207. https://doi.org/10.1080/14796694.2025.2479374
  3. Yip SM, Wells C, Moreira R, Wong A, Srinivas S, Beuselinck B, Porta C, Sim HW, Ernst DS, Rini BI, Yuasa T, Basappa NS, Kanesvaran R, Wood LA, Canil C, Kapoor A, Fu SYF, Choueiri TK, Heng DYC. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Cancer. 2018 Sep 15; 124(18):3677-3683. doi:10.1002/cncr.31595
  4. Yip SM, Laird AD, Agarwal N, Zschäbitz S, Fizazi K, Matsubara N, Joung JY, Karsh LI, Carles J, Fay AP, Piulats JM, Fong PCC, Liu G, Albacker LA, Pasquina LW, Chelliserry J, Healy CG Lin X, Kalac M,. Azad AA. Circulating Tumour DNA and Cells as Prognostic and Predictive Biomarkers of Efficacy in, and Molecular Profiling of, Patients with mCRPC in the TALAPRO-2 Study. Lancet Oncology (In Review)